Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
11:17am, Friday, 10'th Nov 2023
Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful imp
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
07:32pm, Wednesday, 01'st Nov 2023
The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
07:32pm, Monday, 09'th Oct 2023
Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both
07:18pm, Friday, 22'nd Sep 2023
Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-i
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
01:32pm, Thursday, 21'st Sep 2023
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know
07:32pm, Wednesday, 13'th Sep 2023
Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.
Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up
09:50am, Tuesday, 12'th Sep 2023
Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
08:00am, Wednesday, 23'rd Aug 2023
WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' prob
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
06:54pm, Monday, 07'th Aug 2023
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.36 per share a year ago.
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
07:55am, Wednesday, 26'th Jul 2023
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.
Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem
08:37pm, Tuesday, 25'th Jul 2023
Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/year market. Pharmacokinetic studies have shown fa
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' pro
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' prob
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
11:09am, Friday, 14'th Jul 2023
Here is how Aquestive Therapeutics (AQST) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
